MUDr. Dana Maňasková


Vyhledávání na medicinman.cz
 

Tumorové markery

BCL-2 oncoprotein

  • Associated with the development of androgen-independent prostate cancer
  • High levels of expression in androgen-independent tumours in advanced stages of the pathology
  • Upregulation of BCL-2
    • After androgen ablation in prostate carcinoma cell lines
    • In a castrated-male rat model
      • Further established a connection between BCL-2 expression and prostate cancer progression [11]

Ki-67 expression

  • By immunohistochemistry
  • Significant predictor of patient outcome for men with prostate cancer [11]

PSMA

  • Can serve as a marker or identifier for prostate cancer cells


Markery

Metabolity stanovované v diagnostickém panelu H NMR spectroscopy

  • Sarcosine, cysteine, glutamate, asparagines, glycine, leucine, proline, threonine, histidine, n-acetyl-aspartic acid, inosine, inositol, adenosine, taurine, creatine, uric acid, glutathione, uracil, kynurenine, glycerol-s-phosphate, glycocholic acid, suberic acid, glutamic acid, xanthosine, 4-acetamidobutyric acid and thymine [1]
  • Methyl histidine and proline
    • In blood, serum, plasma as well as urine [1]
    • Can be used to determine breast cancer, lung cancer, colon cancer and prostate cancer [1]
    • Limited set gives a higher specificity and selectivity than the complete metabolome. [1]

Moč PLS-DA analysis

  • Only the integral segments of Methylhistidine and Proline
    • Sensitivity of 100% and a specificity of 100%
  • Changes in the different metabolites included in the panel
Literatura:
[1] Patent WO2011128256A1 - Metabolic markers for diagnosing of cancer - Patenty Google [Internet]. [citován 4. červen 2013]. Dostupné od: www.google.com/patents/WO2011128256A1?cl=en&hl=cs&dq=%2215454-75-8%22+OR+%225-oxoproline%22+OR+%22proline,+5-oxo-%22+OR+%225-Carboxy-2-pyrrolidinone%22+OR+%225-Oxo-2-pyrrolidincarbons%C3%A4ure%22+OR+%222-Pyrrolidone-5-carboxylic+acid+%22+OR+%225-OXO-2-PYRROLIDINECARBOXYLIC+ACID%22&source=uds


Isentress (raltegravir)

  • Can inhibit a virus linked to prostate cancer and chronic fatigue syndrome
    • According to a press release from Emory University in Atlanta
  • In 2006, xenotropic murine leukemia virus (XMRV) has been detected in some prostate cancer patients’ tumor biopsies
  • Whittemore Peterson Institute in Nevada has suggested that XMRV is the causative agent of chronic fatigue syndrome in a majority of patients
  • Singh led another recently published study demonstrating the presence of XMRV in 27 percent of prostate cancers examined
    • Virus more likely to be found in the most-aggressive tumors
  • XMRV may promote cancer by integrating into the host cell DNA and warping the cell’s ability to regulate its own genes.
  • Both XMRV and HIV are retroviruses - similar traits and treatment approaches.
  • Tested 45 approved and experimental ARVs and other antiviral compounds against XMRV in cell culture.
  • The most potent drug against XMRV was Isentress
    • Originally approved in 2007 for treatment-experienced patients.
  • Three other compounds—another integrase inhibitor
    • In addition to zidovudine (found in Retrovir, Combivir and Trizivir)
    • And tenofovir (found in Viread, Truvada and Atripla),
    • Two reverse transcriptase inhibitors—also inhibit XMRV replication.
  • Could be used together in combination therapy, much like they’re used to treat HIV.
  • None of the protease inhibitors stopped XMRV in test tube studies.
  • Drugs inhibited XMRV at lower concentrations when two of them were used together
  • www.poz.com/article/hiv-xmrv-raltegravir-18278-7136
O úroveň výše

Poslední aktualizace: 10. 12. 2023 21:59:56